Huan Ma1, Cong Nie1, Ying Chen, Jinmiao Li, Yanjie Xie, Zhixin Tang, Yang Gao, Siming Ai,
Yuxiang Mao, Qian Sun, Rong Lu
Oncology Research, Vol.28, No.7-8, pp. 745-761, 2020, DOI:10.3727/096504021X16130322409507
Abstract Cell cycle deregulation is involved in the pathogenesis of many cancers and is often associated with protein
kinase aberrations, including the polo-like kinase 1 (PLK1). We used retinoblastoma, an intraocular malignancy that lacks targeted therapy, as a disease model and set out to reveal targetability of PLK1 with a small
molecular inhibitor ON-01910.Na. First, transcriptomic analysis on patient retinoblastoma tissues suggested
that cell cycle progression was deregulated and confirmed that PLK1 pathway was upregulated. Next, antitumor activity of ON-01910.Na was investigated in both cellular and animal levels. Cytotoxicity induced by
ON-01910.Na was tumor specific and dose dependent in retinoblastoma cells,… More >
Login
Register
